Furthermore, Galapagos plans to unveil the novel
'We are excited by the rapid progress of GLPG3970 in the clinic,' said Dr.
CALOSOMA study: Phase 1 trial in psoriasis
The Calosoma Phase 1 trial (NCT04106297) is a double-blind, placebo-controlled study evaluating the safety, tolerability, PK and PD1 of GLPG3970 single and multiple ascending doses in up to 52 adult healthy male subjects. GLPG3970 will now be investigated for 6 weeks in 25 subjects with moderate to severe psoriasis. The first patient was dosed recently.
SEA TURTLE study: Phase 2 trial in ulcerative colitis
This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 30 subjects with moderately to severely active UC. GLPG3970 or a placebo will be administered orally once daily for 6 weeks, with the primary endpoint of change from baseline in total Mayo Clinical Score (MCS).
LADYBUG study: Phase 2 trial in rheumatoid arthritis
This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 25 participants with severely active RA and an inadequate response to methotrexate. GLPG3970 or a placebo will be administered orally once-daily for 6 weeks, with the primary endpoint of change from baseline of DAS28 CRP at week 6. Recruitment will take place in
Toledo Roundtable
Galapagos cordially invites institutional investors and analysts to attend our inaugural Roundtable dedicated to
About
'
GLPG3970 is an investigational drug and its efficacy and safety have not been established.
About Galapagos
Contact:
Tel: +1 781 460 1784
Forward-looking statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to dier materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG3970 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG3970 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties and that Galapagos' estimations regarding its GLPG3970 development program and regarding the commercial potential of GLPG3970, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended
(C) 2020 Electronic News Publishing, source